CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 77 enrolled
Drug / intervention
Y14 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03673111
NCT03673111Phase 1Completed
CompareCT.gov

A Randomised, Placebo Controlled First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Y14 in Adult Subjects

Imperial College London·interventional·Posted Sep 17, 2018·Updated Mar 18, 2025

In Brief

A Phase 1 clinical trial evaluating Y14 and Placebo for Diabetes Mellitus and Obesity. Completed, enrolled 77 participants across 1 site.

Detailed Summary

A randomised, placebo controlled Phase I study to investigate investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of Y14 in adult subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Obesity
CountriesUnited Kingdom
CollaboratorsMedical Research Council, Covance

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedSep 17, 2018
Enrollment StartApr 10, 2017
Primary CompletionFeb 13, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.8 years ago

Interventions

Y14drug

Gut hormone analogue

Placebodrug

0.9% saline